Diagnostic Accuracy of DNA Ploidy for Oral Potentially Malignant Disorders: A Systematic Review and Meta Analysis

DNA倍性检测在口腔潜在恶性疾病诊断中的准确性:系统评价和荟萃分析

阅读:1

Abstract

OBJECTIVE: to compare the diagnostic accuracy of DNA ploidy compared to biopsy followed by histopathological investigation in patients with oral potentially malignant disorders (OPMDs). METHOD: The review protocol is registered under PROSPERO(CRD42024524656) and performed in accordance to Preferred Reporting Items for Systematic Reviews and Meta-Analysis - Diagnostic Test Accuracy (PRISMA- DTA) checklist. Databases like PubMed, Google Scholar, EBSCOhost were searched from 2000 to 2024 to identify the diagnostic potential of DNA ploidy for various OPMDs. True-positive, false-positive, true-negative, false-negative, sensitivity, specificity values were calculated manually if not present for each study. Quality assessment of included studies was evaluated based on Quality assessment of diagnostic accuracy studies (QUADAS)- 2 tool using review manager (RevMan ver. 5.3). Meta-analysis was performed in Meta-Disc 1.4 software for pooled sensitivity and specificity. Additional analysis was performed in terms of positive likelihood ratio (+LR), negative likelihood ratio (-LR), diagnostic odds ratio (DOR) and summary receiver operating characteristics (SROC) with Area Under Curve (AUC) and p<0.05 as statistically significant. RESULTS: Nine studies were included for qualitative synthesis and seven studies for meta-analysis. Included studies reported low risk of bias (ROB). Various OPMDs (oral leukoplakia (OL), oral lichen planus (OLP), erythroplakia (OE), oral erythro-leukoplakia and other oral dysplastic lesions were evaluated. The meta-analysis revealed an overall pooled sensitivity of 0.71 (CI 0.28- 0.96) and pooled specificity of 0.31 (CI 0.03- 0.79) with +PLR 0.99 (0.49 - 2.02) and -NLR 0.99 (0.18 - 5.48) and a DOR of 1.05 (0.07 - 16.14) with an overall diagnostic accuracy (AUC) of 0.49. CONCLUSION: This study findings provide evidence on ability of DNA ploidy for various OPMDs for early screening and diagnosis. DNA ploidy can be taken for secondary level of prevention for OPMD under early diagnosis and prompt treatment.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。